EHS
EHS

Keytruda Granted Accelerated Approval for Treatment of HCC



The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor accelerated approval for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib.

Source link

EHS
Back to top button